Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine
Chris Anselmo, who has a rare form of muscular dystrophy, hopes to educate pharma on the patient journey and help new patients cope with a life-changing diagnosis.
Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d